Unlock instant, AI-driven research and patent intelligence for your innovation.

Dry Powder Formulations for Messenger RNA

a technology of messenger rna and powder formulation, which is applied in the direction of spray delivery, peptide/protein ingredients, aerosol delivery, etc., can solve the problems of poor yield and unsatisfactory particle characteristics, and achieve the effect of more efficient mrna delivery, less undesirable particle characteristics, and more efficacy of mrna therapy

Pending Publication Date: 2021-12-09
TRANSLATE BIO INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0004]The present invention provides, among other things, a dry powder (i.e., spray-dried) formulation of mRNA encapsulated with lipid based nanoparticles for more efficient mRNA delivery and more efficacious mRNA therapy. Prior to the present invention, one of the challenges of spray-drying lipid nanoparticle-encapsulated mRNA arose from the fact that both mRNA and the lipid nanoparticle components are structurally labile at the high temperatures and / or pressures needed for adequate spray-drying. For example, an inlet temperature of a spray-dryer ranges between 80° C. to 98° C. Lipids tend to melt and / or aggregate at the high inlet temperature at or near the spray nozzle. This causes hindrance to the flow of the formulation through the nozzle into the drying chamber, disrupts uniform dispersion of the spray and produces undesirable particle characteristics and poor yield. The present invention has unexpectedly solved this problem with the addition of a polymer to the mRNA and lipid nanoparticle mixture before subjecting the mixture to the spray-drying process. As described herein, the inventors observed that adding a polymer to an mRNA and lipid mixture effectively prevents aggregation of lipid nanoparticles and facilitates dry powder formation of fine particles containing mRNA-loaded lipid nanoparticles suitable for inhalation.
[0005]More surprisingly, despite the extremely unstable nature of mRNA, dry powder formulations prepared according to the present invention, even under high temperatures and / or high pressures associated with spray-drying, are stable and able to maintain a high degree of mRNA integrity even after long term storage at various temperatures. In addition, a dry powder formulation prepared according to the present invention is also characterized with high LNP encapsulation efficiency of mRNA, resulting in high cellular delivery of mRNA. Therefore, the present invention fulfils a long-standing need in the mRNA therapy field for a stable dry powder form of mRNA therapeutic, which can easily be stored, transferred, and dispensed. Further, the dry powder formulations of mRNA according to the present invention can be administered as dry powder to a patient, e.g. in metered doses or weighed out and reconstituted in single-use amounts, without the need for freezing single-use aliquots of liquid.

Problems solved by technology

This causes hindrance to the flow of the formulation through the nozzle into the drying chamber, disrupts uniform dispersion of the spray and produces undesirable particle characteristics and poor yield.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry Powder Formulations for Messenger RNA
  • Dry Powder Formulations for Messenger RNA
  • Dry Powder Formulations for Messenger RNA

Examples

Experimental program
Comparison scheme
Effect test

example 1

Dry Powder Formulations Recovered from Spray-Drying

[0238]In this example, LNP-encapsulated mRNA formulations were prepared with and without polymer and spray-dried. The results show that the LNP-encapsulated mRNA formulations prepared with polymer provides an unexpected high recovery from the spray-dry process, as compared to the same mRNA-LNP formulations prepared without polymer.

[0239]In particular, two of LNP-encapsulated mRNA formulations (mRNA encoding Firefly Luciferase (FFL) and formulations referred to as FFL-F1 an FFL-F2, respectively) each were prepared without polymer or with polymer, with the individual compositions of each described in Table 1. To prepare these formulations for spray-drying, the FFL mRNA was first mixed with lipid nanoparticles (LNPs) using a gear pump in order to encapsulate the mRNA within the LNPs. Then, for the “With Polymer” samples, the polymer solution then was mixed with mRNA-LNPs using a gear pump. The solutions were then subjected to spray-dry...

example 2

and Stability of mRNA Dry Powder Formulations

[0242]In this example, two mRNA formulations encoding argininosuccinate synthetase or ASS1 mRNA were prepared and assessed for long-term stability. In particular, one mRNA formulation was prepared that included no LNP but did include polymer (ASS1-F1). A second mRNA formulation was prepared that included LNP-encapsulated LNP plus polymer (ASS-F2). Each formulation is described further in Table 2.

[0243]For the ASS1-F1 formulation, the mRNA was directly mixed with the polymer using a gear pump. For the ASS1-F2 formulation, the mRNA was first mixed with lipid nanoparticles (LNPs) using a gear pump in order to encapsulate the mRNA within the LNPs and then the polymer solution was mixed with the mRNA-LNPs using a gear pump. The final formulations were concentrated, and mannitol was added to each formulation. The solutions were then subjected to spray-drying as depicted in the graphical representation of the instrumentation in FIG. 1. The follo...

example 3

Method of mRNA Encapsulation in Lipid-Polymer Nanoparticle

[0253]In this example, lipids, mRNA and polymer were prepared in a single step to produce lipid-polymer-encapsulated mRNA nanoparticles (formulations ASS1-F3 With Polymer and ASS1-F4 With Polymer). This is in contrast to Example 1 and Example 2 where LNP-encapsulating mRNA nanoparticles were first prepared and then polymer was added into the formulation. In addition, reference formulations were prepared by the same process but without including polymer in the nanoparticle or formulation (formulations ASS1-F3 Without Polymer and ASS1-F4 Without Polymer).

[0254]In particular, lipids and polymer (or just lipids for the control formulations) were dissolved in ethanol and together mixed with mRNA solution using a gear pump. Four different formulations were prepared. The first and second formulations (ASS1-F3 Without Polymer and ASS1-F3 With Polymer) were prepared with cKK-E12 as the cationic lipid, either without or with polymer. T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application No. 62 / 702,193 filed Jul. 23, 2018; incorporated by reference herein in its entirety.SEQUENCE LISTING[0002]This application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 19, 2019, is named MRT_2008WO_SeqListing.txt and is 1137 byte in size.BACKGROUND[0003]Messenger RNA therapy (MRT) is becoming an increasingly important approach for the treatment of a variety of diseases. Lipid encapsulated mRNA formulations, such as lipid nanoparticle (LNP) compositions show high degree of cellular uptake and protein expression. However, presently these formulations are typically in liquid forms, and are required to be administered usually in the form of injections, or via nebulizers. These modes of administration are less desired by the patient than some le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/51A61K38/17A61K48/00A61K9/50A61K38/45A61K9/00
CPCA61K9/5123A61K38/177A61K48/0075A61K9/5153A61K38/45A61K9/0075A61K9/0078A61K9/5089A61K9/0073A61K9/1275A61K9/16A61K9/1629A61K9/1635A61K9/1617A61K9/513A61P11/00A61K9/4866A61K9/5015A61K9/5031A61K38/1709A61K48/0033
Inventor KARVE, SHRIRANGDEROSA, FRANKHEARTLEIN, MICHAELPATEL, ZARNASARODE, ASHISH
Owner TRANSLATE BIO INC